A groundbreaking Phase IIa clinical trial in South Africa has demonstrated that a combination of broadly neutralizing antibodies and immune stimulants may enable some HIV patients to control the virus without daily antiretroviral therapy.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.